2023年6月13日

分享这篇文章提供的新闻分享本文极光,科罗拉多州,6月13日2023 /远见诊断,从领导者在超灵敏的微小残留病(MRD)检测技术,今天宣布,马克Roschewski,医学博士,美国国家癌症研究所,国立卫生研究院的一部分,将汇集的数据最近六个临床研究在第17届国际会议6月14日在卢加诺的恶性淋巴瘤,瑞士。“我们很高兴有机会共享数据从这些有效的临床研究在即将举行的国际会议上恶性淋巴瘤,”杰克Chabon说,博士,首席执行官和共同创始人的远见诊断。在远见诊断“我们的目标是改善病人护理,提供行业领先的MRD检测。博士所提出的这项研究Roschewski表明我们PhasED-Seq™技术正在向实现这一目标的道路上通过提供信息,医生可能会让患者的重要治疗决策。我们感谢Roschewski博士提出这一重要工作和所有的作者,患者和家庭使这样的研究成为可能。”The abstract to be presented by Dr. Roschewski is based on six pooled frontline clinical studies that used Foresight Diagnostics' ultrasensitive PhasED-Seq technology to quantify MRD in 365 samples from 141 patients with diffuse large B-cell lymphoma (DLBCL). Samples were taken at timepoints before, during, or at the end of treatment and were profiled using PhasED-Seq at either Foresight Diagnostics' CLIA laboratory or Stanford University. When MRD status at a variety of time points before, during, and after treatment were compared to clinical outcomes, the authors found that MRD status at the end of treatment identified patients at the highest risk of progression. Importantly, PhasED-Seq was significantly more sensitive than PET/CT imaging at the end of treatment for identifying patients who later relapsed, with PhasED-Seq correctly identifying 90% of patients who later relapse compared to 45% of patients identified by PET/CT. These results suggest that MRD measured using PhasED-Seq at the end of treatment is highly prognostic in patients with DLBCL and that ultrasensitive assays like PhasED-Seq should be considered in the revised Lugano response criteria. Podium Presentation Information: Presenting Author: Mark Roschewski, MD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD Session Date: Wednesday, June 14, 2023, at 9:20 AM GMT (5:20 PM CEST); "Focus On…" Session – Liquid Biopsy and Minimum Residual Disease, Auditorium About Foresight Diagnostics Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive (with a detection limit below 0.0001%, or one part-per-million) than existing tests. The improved sensitivity of the Foresight lymphoma MRD assay can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with B-cell malignancies. Foresight is developing an MRD assay for other tumor types based on the same technology. For more information, please visit foresight-dx.com and follow us on Twitter and LinkedIn . About PhasED-Seq The Foresight MRD platform is based on the Phased variant Enrichment and Detection by Sequencing (PhasED-Seq™) technology. PhasED-Seq lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%). PhasED-Seq has been extensively validated in hundreds of patients with B-cell lymphomas. Contact Foresight